NASDAQ:BFRI Biofrontera Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.78 -0.08 (-4.30%) (As of 07/1/2022 03:27 PM ET) Add Compare Share Today's Range$1.78▼$1.9150-Day Range$1.86▼$4.0652-Week Range$1.80▼$14.63Volume7,612 shsAverage Volume2.00 million shsMarket Capitalization$33.74 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BFRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Email Address BFRI Stock Forecast (MarketRank)Overall MarketRank™1.38 out of 5 starsMedical Sector1111th out of 1,429 stocksPharmaceutical Preparations Industry549th out of 682 stocksAnalyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingBiofrontera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.50, Biofrontera has a forecasted upside of 770.8% from its current price of $1.78.Amount of Analyst CoverageBiofrontera has received no research coverage in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesBiofrontera has received 3 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBiofrontera has received 4 “underperform” votes. (Add your “underperform” vote.)Community SentimentBiofrontera has received 57.14% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Biofrontera and other stocks. Vote “Outperform” if you believe BFRI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BFRI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBiofrontera does not currently pay a dividend.Dividend GrowthBiofrontera does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biofrontera insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 4.10% of the stock of Biofrontera is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biofrontera are expected to grow in the coming year, from ($0.74) to ($0.38) per share.Price to Book Value per Share RatioBiofrontera has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biofrontera (NASDAQ:BFRI)Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Read More BFRI Stock News HeadlinesJune 9, 2022 | finance.yahoo.comBiofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing ExcellenceJune 8, 2022 | streetinsider.comForm F-6 POS Biofrontera AG/ADR Filed by: BANK OF NEW YORK / ADR DIVISION - StreetInsider.comMay 31, 2022 | finance.yahoo.comBiofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 ConferenceMay 24, 2022 | globenewswire.comNew Data and Forecasts for the US Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera's Ameluz - GlobeNewswireMay 24, 2022 | finance.yahoo.comNew Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera’s Ameluz®May 19, 2022 | seekingalpha.comBiofrontera AG (BFAGY) Management on Q1 2022 Results - Earnings Call Transcript - Seeking AlphaMay 19, 2022 | finance.yahoo.comBiofrontera Inc. Announces Closing of $9.4 Million Private PlacementMay 19, 2022 | globenewswire.comBiofrontera Inc. Announces Closing of $9.4 Million Private Placement - GlobeNewswireMay 16, 2022 | seekingalpha.comBiofrontera prices $9.4M securities offering - Seeking AlphaMay 16, 2022 | finance.yahoo.comBiofrontera Inc. Announces Pricing of $9.4 Million Private PlacementMay 13, 2022 | finance.yahoo.comBiofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business UpdateMay 6, 2022 | finance.yahoo.comBiofrontera Inc. to Report First Quarter Financial Results on May 13, 2022May 6, 2022 | globenewswire.comBiofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser Education - GlobeNewswireSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BFRI CUSIPN/A CIK1858685 Webwww.biofrontera-us.com Phone781-245-1325FaxN/AEmployees69Year FoundedN/ACompany Calendar Last Earnings4/08/2022Today7/01/2022Next Earnings (Estimated)8/12/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$15.50 High Stock Price Forecast$20.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+770.8%Consensus RatingBuy Rating Score (0-4)3 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.05 Sales & Book Value Annual Sales$24.10 million Price / Sales1.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book2.70Miscellaneous Outstanding Shares18,955,000Free FloatN/AMarket Cap$33.74 million OptionableNot Optionable BetaN/A Biofrontera Frequently Asked Questions Should I buy or sell Biofrontera stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Biofrontera stock. View analyst ratings for Biofrontera or view top-rated stocks. What is Biofrontera's stock price forecast for 2022? 2 Wall Street research analysts have issued 12 month target prices for Biofrontera's shares. Their BFRI stock forecasts range from $11.00 to $20.00. On average, they predict Biofrontera's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 770.8% from the stock's current price. View analysts' price targets for Biofrontera or view top-rated stocks among Wall Street analysts. How has Biofrontera's stock performed in 2022? Biofrontera's stock was trading at $7.52 at the beginning of 2022. Since then, BFRI stock has decreased by 76.3% and is now trading at $1.78. View the best growth stocks for 2022 here. When is Biofrontera's next earnings date? Biofrontera is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Biofrontera. How were Biofrontera's earnings last quarter? Biofrontera Inc. (NASDAQ:BFRI) posted its quarterly earnings data on Friday, April, 8th. The company reported ($0.42) earnings per share (EPS) for the quarter. The business had revenue of $9.17 million for the quarter. View Biofrontera's earnings history. What guidance has Biofrontera issued on next quarter's earnings? Biofrontera issued an update on its FY 2022 earnings guidance on Friday, June, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $31.33M-, compared to the consensus revenue estimate of $40.70 million. Who are Biofrontera's key executives? Biofrontera's management team includes the following people: Dr. Hermann Lubbert Ph.D., Exec. Chairman & Pres (Age 66, Pay $18.02k)Ms. Erica L. Monaco CPA, CEO, CFO, COO, Treasurer & Sec. (Age 37, Pay $402.12k)Ms. Erica F. Gates CPA, M.B.A., Sr. Director of Fin. & Principal Accounting OfficerMr. Daniel Hakansson J.D., Gen. Counsel & Head of ComplianceMr. Mark Baldyga, Head of Sales & MarketingMr. Jeff Holm, Head of Professional Relations & Commercial Devel. Who are some of Biofrontera's key competitors? Some companies that are related to Biofrontera include scPharmaceuticals (SCPH), Immuneering (IMRX), Citius Pharmaceuticals (CTXR), IO Biotech (IOBT), Anebulo Pharmaceuticals (ANEB), ProMetic Life Sciences (PFSCF), NextCure (NXTC), Nanobiotix (NBTX), Atossa Therapeutics (ATOS), ContraFect (CFRX), Endo International (ENDP), ESSA Pharma (EPIX), Puma Biotechnology (PBYI), CytomX Therapeutics (CTMX) and LumiraDx (LMDX). View all of BFRI's competitors. When did Biofrontera IPO? (BFRI) raised $19 million in an initial public offering on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company served as the underwriters for the IPO. What is Biofrontera's stock symbol? Biofrontera trades on the NASDAQ under the ticker symbol "BFRI." How do I buy shares of Biofrontera? Shares of BFRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biofrontera's stock price today? One share of BFRI stock can currently be purchased for approximately $1.78. How much money does Biofrontera make? Biofrontera (NASDAQ:BFRI) has a market capitalization of $33.74 million and generates $24.10 million in revenue each year. How many employees does Biofrontera have? Biofrontera employs 69 workers across the globe. How can I contact Biofrontera? The official website for Biofrontera is www.biofrontera-us.com. The company can be reached via phone at 781-245-1325 or via email at [email protected]. This page (NASDAQ:BFRI) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
